Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

  1. Rosiñol, L.
  2. Hebraud, B.
  3. Oriol, A.
  4. Colin, A.-L.
  5. Ríos Tamayo, R.
  6. Hulin, C.
  7. Blanchard, M.J.
  8. Caillot, D.
  9. Sureda, A.
  10. Hernández, M.T.
  11. Arnulf, B.
  12. Mateos, M.-V.
  13. Macro, M.
  14. San-Miguel, J.
  15. Belhadj, K.
  16. Lahuerta, J.J.
  17. Garelik, M.B.
  18. Bladé, J.
  19. Moreau, P.
Aldizkaria:
Frontiers in Oncology

ISSN: 2234-943X

Argitalpen urtea: 2023

Alea: 13

Mota: Artikulua

DOI: 10.3389/FONC.2023.1197340 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus